文献速递皮肤肿瘤

Ⅰ至Ⅱ期皮肤黑色素瘤淋巴与血行播散的危险因素

Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma.
PubMed 文献 · JAMA Dermatol · 2019-01-01

西班牙瓦伦西亚肿瘤研究所回顾性纳入1177例Ⅰ至Ⅱ期恶性黑色素瘤患者,中位随访75个月,淋巴与血行转移各108例(9.2%)。多因素分析显示两条转移途径的危险因素不同:淋巴转移与年龄>55岁、头颈及肢端部位、较大Breslow厚度、血管侵犯相关;血行转移与较大Breslow厚度、无消退、TERT启动子突变及BRAF突变相关。

要点

  • 淋巴转移与血行转移的危险因素不同,随访与辅助治疗策略可按个体临床、组织病理和分子特征调整。
  • Breslow厚度>4.00 mm与淋巴转移(HR 5.4)和血行转移(HR 10.4)风险升高均相关。
  • TERT启动子突变与BRAF突变与血行转移风险升高相关。

核心结论

  • 淋巴与血行转移的危险因素不同,随访和辅助治疗策略可依个体临床、组织病理和分子特征调整。

研究设计与样本

  • 回顾性队列研究,纳入西班牙Instituto Valenciano de Oncología治疗的1177例恶性黑色素瘤患者,数据取自2000年1月1日至2015年12月31日的黑色素瘤数据库。
  • 采用Kaplan-Meier曲线和Cox比例风险回归分析无淋巴转移生存与无血行转移生存。

主要发现

  • 1177例患者中51.1%为女性,诊断时中位年龄55岁(四分位距42-68岁),中位随访75个月(四分位距33-121个月)。
  • 108例(9.2%)发生淋巴转移,108例(9.2%)发生血行转移。
  • 淋巴转移多因素分析:年龄>55岁HR 1.9(95%CI 1.2-3.1),头颈部位HR 1.7(95%CI 1.0-2.9),肢端部位HR 2.4(95%CI 1.3-4.5),Breslow厚度>4.00 mm HR 5.4(95%CI 2.4-12.4),血管侵犯HR 3.2(95%CI 0.9-10.6)。
  • 血行转移多因素分析:Breslow厚度>4.00 mm HR 10.4(95%CI 3.6-29.7),无消退HR 0.1(95%CI 0.0-1.0),TERT启动子突变HR 2.9(95%CI 1.5-5.7),BRAF突变HR 1.9(95%CI 1.1-3.6)。

临床怎么用

  • 对Ⅰ至Ⅱ期黑色素瘤应分别评估淋巴与血行转移风险,结合年龄、部位、Breslow厚度、血管侵犯及TERT启动子、BRAF突变状态制定个体化随访与辅助治疗策略。

局限性

  • 为单中心回顾性队列研究,结果需外部验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: The lymphatic and the hematogenous pathways have been proposed for disease progression in cutaneous melanoma, but association with recurrence has not been studied separately to date. OBJECTIVE: To identify the risk factors associated with lymphatic and hematogenous metastasis. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study included 1177 patients with malignant melanoma treated at Instituto Valenciano de Oncología, València, Spain. Data were retrieved from the melanoma database from January 1, 2000, through December 31, 2015, and analyzed from June 1 to 30, 2018. EXPOSURE: Malignant melanoma at stages I to II. MAIN OUTCOMES AND MEASURES: Analyses of survival free of lymphatic and hematogenous metastasis were performed using Kaplan-Meier curves and Cox proportional hazards regression. RESULTS: For the 1177 patients included in the study analysis (51.1% women; median age at diagnosis, 55 years [interquartile range, 42-68 years), median follow-up was 75 months (interquartile range, 33-121 months); 108 (9.2%) developed lymphatic metastasis, and 108 (9.2%) developed hematogenous metastasis. In the multivariate analysis, being older than 55 years (hazard ratio [HR], 1.9; 95% CI, 1.2-3.1), tumor in the head/neck (HR, 1.7; 95% CI, 1.0-2.9) and acral locations (HR, 2.4; 95% CI, 1.3-4.5), greater Breslow thickness (HR for >4.00 mm, 5.4; 95% CI, 2.4-12.4), and presence of vascular invasion (HR, 3.2; 95% CI, 0.9-10.6) were associated with lymphatic spreading. Hematogenous metastasis was associated with greater Breslow thickness (HR for >4.00 mm, 10.4; 95% CI, 3.6-29.7), the absence of regression (HR, 0.1; 95% CI, 0.0-1.0), TERT promoter mutations (HR, 2.9; 95% CI, 1.5-5.7), and BRAF mutations (HR, 1.9; 95% CI, 1.1-3.6). CONCLUSIONS AND RELEVANCE: Risk factors associated with lymphatic and hematogenous metastasis differ. Follow-up and adjuvant treatment strategies may therefore need to be adapted to individual clinical, histopathologic, and molecular characteristics.

来源:JAMA Dermatol,查看原文。版权归原作者所有。

引用

  1. Calomarde-Rees L, García-Calatayud R, Requena Caballero C, et al. Risk Factors for Lymphatic and Hematogenous Dissemination in Patients With Stages I to II Cutaneous Melanoma. JAMA Dermatol. 2019. PMID: 31042264. doi:10.1001/jamadermatol.2019.0069

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。